Oral presentation at 22nd Annual WORLDSymposium highlights sustained knockdown of GYS1 mRNA, favorable safety and tolerability, predictable pharmacokinetics, and biomarker reductions consistent with ...
Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...
Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...
Please provide your email address to receive an email when new articles are posted on . Three phase 2 trials demonstrated the efficacy and safety of RNA interference therapy for the treatment of mixed ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
In such individuals, known to be at increased risk of atherosclerotic cardiovascular disease (ASCVD), plozasiran at various doses conferred significantly larger reductions over placebo in fasting ...
Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will focus ...
Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months ...
Please provide your email address to receive an email when new articles are posted on . The receptor for advanced glycation end-products (RAGE) regulates pathways that contribute to inflammation.
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results